TRMT6

Summary

TRMT6 (tRNA methyltransferase 6 non-catalytic subunit, HGNC:20900) is a protein-coding gene on chromosome 20p12.3, encoding tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6 (Q9UJA5). Substrate-binding subunit of tRNA (adenine-N(1)-)-methyltransferase, which catalyzes the formation of N(1)-methyladenine at position 58 (m1A58) in initiator methionyl-tRNA. It is a selective cancer dependency (DepMap: 35.5% of cell lines).

This gene encodes a member of the tRNA methyltransferase 6 protein family. A similar protein in yeast is part of a two component methyltransferase, which is involved in the posttranslational modification that produces the modified nucleoside 1-methyladenosine in tRNAs. Modified 1-methyladenosine influences initiator methionine stability and may be involved in the replication of human immunodeficiency virus type 1. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 51605 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 70 total
• Cancer dependency (DepMap): dependent in 35.5% of screened cell lines
• MANE Select transcript: NM_015939

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20900
Approved symbol	TRMT6
Name	tRNA methyltransferase 6 non-catalytic subunit
Location	20p12.3
Locus type	gene with protein product
Status	Approved
Aliases	GCD10, MGC5029, Gcd10p, CGI-09
Ensembl gene	ENSG00000089195
Ensembl biotype	protein_coding
OMIM	620886
Entrez	51605

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000203001, ENST00000453074, ENST00000466974, ENST00000473131, ENST00000493972, ENST00000931286, ENST00000931287, ENST00000931288, ENST00000931289

RefSeq mRNA: 2 — MANE Select: NM_015939 NM_001281467, NM_015939

CCDS: CCDS13093, CCDS63225

Canonical transcript exons

ENST00000203001 — 11 exons

Exon	Start	End
ENSE00001714451	5950278	5950533
ENSE00003478761	5943948	5944031
ENSE00003508092	5941243	5941345
ENSE00003526050	5946406	5946533
ENSE00003533977	5941053	5941139
ENSE00003571966	5942428	5942786
ENSE00003596634	5943559	5943683
ENSE00003606889	5944805	5944914
ENSE00003631145	5944162	5944253
ENSE00003639501	5941951	5942036
ENSE00003847622	5937228	5938726

Expression profiles

Bgee: expression breadth ubiquitous, 257 present calls, max score 96.44.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.9188 / max 267.7466, expressed in 1770 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
186334	11.2748	1759
186333	2.6439	1050

Top tissues by expression

258 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	96.44	gold quality
oocyte	CL:0000023	96.22	gold quality
upper arm skin	UBERON:0004263	91.35	gold quality
nipple	UBERON:0002030	90.14	gold quality
kidney epithelium	UBERON:0004819	89.69	gold quality
seminal vesicle	UBERON:0000998	89.31	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.08	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.07	gold quality
cerebellar vermis	UBERON:0004720	88.73	gold quality
parotid gland	UBERON:0001831	87.48	gold quality
nasal cavity epithelium	UBERON:0005384	87.37	gold quality
pons	UBERON:0000988	87.24	gold quality
bone marrow	UBERON:0002371	87.21	gold quality
islet of Langerhans	UBERON:0000006	86.58	gold quality
monocyte	CL:0000576	86.51	gold quality
gastrocnemius	UBERON:0001388	86.45	gold quality
pericardium	UBERON:0002407	86.41	gold quality
Brodmann (1909) area 23	UBERON:0013554	86.38	gold quality
leukocyte	CL:0000738	86.29	gold quality
pylorus	UBERON:0001166	86.20	gold quality
deltoid	UBERON:0001476	86.18	gold quality
tendon of biceps brachii	UBERON:0008188	86.16	gold quality
mammalian vulva	UBERON:0000997	85.97	gold quality
substantia nigra pars compacta	UBERON:0001965	85.85	gold quality
gingival epithelium	UBERON:0001949	85.67	gold quality
renal medulla	UBERON:0000362	85.59	gold quality
muscle of leg	UBERON:0001383	85.49	gold quality
synovial joint	UBERON:0002217	85.49	gold quality
trabecular bone tissue	UBERON:0002483	85.46	gold quality
gingiva	UBERON:0001828	85.39	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	18.46
E-MTAB-9467	yes	11.25
E-GEOD-110499	no	2044.06

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

46 targeting TRMT6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-513C-5P	99.50	68.42	1730
HSA-MIR-514B-5P	99.50	68.19	1766
HSA-MIR-142-5P	99.48	70.92	2416
HSA-MIR-5590-3P	99.48	70.91	2429
HSA-MIR-150-3P	99.43	70.51	920
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-2116-5P	99.32	69.34	1273
HSA-MIR-4324	99.04	70.14	1569
HSA-MIR-4709-3P	98.88	68.04	1594

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 35.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 4)

• TRMT6 was upregulated in HCC tissues, and higher TRMT6 expression levels was correlated with reduced OS and RFS in patients with primary HCC. (PMID:31128068)
• N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. (PMID:34728628)
• TRMT6 gene rs236110 C > A polymorphism increases the risk of Wilms tumor. (PMID:37473973)
• Identification of hepatoblastoma susceptibility loci in the TRMT6 gene from a seven-center case-control study. (PMID:37850543)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	trmt6	ENSDARG00000042344
mus_musculus	Trmt6	ENSMUSG00000037376
rattus_norvegicus	Trmt6	ENSRNOG00000021270
drosophila_melanogaster	Trmt6	FBGN0031832
caenorhabditis_elegans	trmt-6	WBGENE00014120

Protein

Protein identifiers

tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6 — Q9UJA5 (reviewed: Q9UJA5)

Alternative names: mRNA methyladenosine-N(1)-methyltransferase non-catalytic subunit TRM6, tRNA(m1A58)-methyltransferase subunit TRM6

All UniProt accessions (1): Q9UJA5

UniProt curated annotations — full annotation on UniProt →

Function. Substrate-binding subunit of tRNA (adenine-N(1)-)-methyltransferase, which catalyzes the formation of N(1)-methyladenine at position 58 (m1A58) in initiator methionyl-tRNA. Together with the TRMT61A catalytic subunit, part of a mRNA N(1)-methyltransferase complex that mediates methylation of adenosine residues at the N(1) position of a small subset of mRNAs: N(1) methylation takes place in tRNA T-loop-like structures of mRNAs and is only present at low stoichiometries.

Subunit / interactions. Heterotetramer; composed of two copies of TRMT6 and two copies of TRMT61A.

Subcellular location. Nucleus.

Tissue specificity. Expressed in brain, liver, testis and ovary.

Similarity. Belongs to the TRM6/GCD10 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9UJA5-1	1	yes
Q9UJA5-2	2
Q9UJA5-3	3
Q9UJA5-4	4

RefSeq proteins (2): NP_001268396, NP_057023* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR017423	TRM6	Family

Pfam: PF04189

Enzyme classification (BRENDA):

• EC 2.1.1.220 — tRNA (adenine58-N1)-methyltransferase (BRENDA: 8 organisms, 17 substrates, 2 inhibitors, 5 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

3 substrates with measured Km, best-characterized 3. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ADENINE58 IN INITIATOR TRNAMET	—	1
ADENINE58 IN TRNAPHE	0.0001	1
S-ADENOSYL-L-METHIONINE	0.005	1

UniProt features (59 total): strand 17, helix 17, binding site 7, region of interest 4, splice variant 4, modified residue 3, sequence variant 3, compositionally biased region 3, chain 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
5CCB	X-RAY DIFFRACTION	2
5CCX	X-RAY DIFFRACTION	2.1
5CD1	X-RAY DIFFRACTION	3.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UJA5-F1	80.02	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (7): 175–182; 349; 377; 415–423; 434–441; 94–104; 145–154

Post-translational modifications (3): 107, 298, 305

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6782315	tRNA modification in the nucleus and cytosol

MSigDB gene sets: 136 (showing top): E2F_Q4, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, E2F4DP1_01, GOBP_TRNA_METABOLIC_PROCESS, CHANDRAN_METASTASIS_DN, GOBP_RNA_METHYLATION, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, WEI_MYCN_TARGETS_WITH_E_BOX, E2F1DP1_01, E2F_Q3, E2F1DP2_01, GOBP_RNA_MODIFICATION, GOBP_TRNA_METHYLATION, GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN

GO Biological Process (3): mRNA processing (GO:0006397), tRNA methylation (GO:0030488), tRNA processing (GO:0008033)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), tRNA (m1A) methyltransferase complex (GO:0031515)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
tRNA processing	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
mRNA metabolic process	1
RNA methylation	1
tRNA modification	1
tRNA metabolic process	1
nucleic acid binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
tRNA methyltransferase complex	1

Protein interactions and networks

STRING

1988 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRMT6	TRMT61A	Q96FX7	999
TRMT6	TRMT61B	Q9BVS5	918
TRMT6	TRMT10C	Q7L0Y3	850
TRMT6	ALKBH1	Q13686	776
TRMT6	METTL1	Q9UBP6	744
TRMT6	WDR4	P57081	718
TRMT6	TRMT5	Q32P41	718
TRMT6	TRMT112	Q9UI30	718
TRMT6	TRMT11	Q7Z4G4	712
TRMT6	NSUN2	Q08J23	711
TRMT6	ALKBH3	Q96Q83	709
TRMT6	FTSJ1	Q9UET6	691
TRMT6	TRUB1	Q8WWH5	676
TRMT6	TRMT10A	Q8TBZ6	661
TRMT6	ADAT3	Q96EY9	645

IntAct

98 interactions, top by confidence:

A	B	Type	Score
SRP9	SRP72	psi-mi:“MI:0914”(association)	0.730
TRMT61A	TRMT6	psi-mi:“MI:0915”(physical association)	0.670
USE1	NBAS	psi-mi:“MI:0914”(association)	0.640
KLHL22	TMEM223	psi-mi:“MI:0914”(association)	0.640
TRMT6	PPIA	psi-mi:“MI:0915”(physical association)	0.560
TRMT6	YWHAG	psi-mi:“MI:0915”(physical association)	0.560
TRMT6	SETDB1	psi-mi:“MI:0915”(physical association)	0.560
TRMT6	KAT5	psi-mi:“MI:0915”(physical association)	0.560
LMO3	TRMT6	psi-mi:“MI:0915”(physical association)	0.560
TRMT61A	ARHGEF11	psi-mi:“MI:0914”(association)	0.530
PTGES3	AIP	psi-mi:“MI:0914”(association)	0.530
MAGEB2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
RPL4	TEFM	psi-mi:“MI:0914”(association)	0.530
TRMT6	FOXJ1	psi-mi:“MI:0915”(physical association)	0.370
TRMT6	HHEX	psi-mi:“MI:0915”(physical association)	0.370
CKAP5	TACC3	psi-mi:“MI:0914”(association)	0.350
NETO2	TIA1	psi-mi:“MI:0914”(association)	0.350

BioGRID (128): TRMT6 (Affinity Capture-MS), TRMT6 (Affinity Capture-MS), TRMT6 (Affinity Capture-MS), TRMT6 (Affinity Capture-MS), DDX5 (Co-fractionation), DNAJC17 (Co-fractionation), EIF2B1 (Co-fractionation), NHP2L1 (Co-fractionation), PUS1 (Co-fractionation), RDX (Co-fractionation), SNW1 (Co-fractionation), STK24 (Co-fractionation), TLN2 (Co-fractionation), TRMT6 (Co-fractionation), TRMT6 (Co-fractionation)

ESM2 similar proteins: A0A3Q1LSX9, A2APV2, A4IHK8, A8K855, A9JRL3, D3Z8X7, O00418, O08796, O35099, O60308, P55265, P70531, Q13905, Q1LX49, Q28CB1, Q3SXY8, Q3UFM5, Q4V8B2, Q5E9V1, Q5QNQ6, Q5R6Y9, Q5R9G1, Q5RHX6, Q62172, Q62796, Q640N2, Q66JG9, Q6DD21, Q6DFA1, Q6ZPF4, Q7Z699, Q7ZYB4, Q80V31, Q80V94, Q8CI95, Q8IVF7, Q8IWE4, Q8K0Q5, Q8K0V2, Q8K4M9

Diamond homologs: Q2T9V5, Q4WE58, Q54UB1, Q8CE96, Q9UJA5, Q2UJ66

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 97 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SRP-dependent cotranslational protein targeting to membrane	7	9.5×	4e-03
Formation of a pool of free 40S subunits	6	9.1×	8e-03
L13a-mediated translational silencing of Ceruloplasmin expression	6	8.2×	8e-03
GTP hydrolysis and joining of the 60S ribosomal subunit	6	8.1×	8e-03
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)	6	7.9×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	6	12.2×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

70 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	53
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1569 predictions. Top by Δscore:

Variant	Effect	Δscore
20:5938726:CCTAA:C	acceptor_loss	1.0000
20:5938727:CTA:C	acceptor_loss	1.0000
20:5941048:CGTA:C	donor_loss	1.0000
20:5941049:GTACC:G	donor_loss	1.0000
20:5941050:TA:T	donor_loss	1.0000
20:5941051:ACC:A	donor_loss	1.0000
20:5941052:CCTGA:C	donor_loss	1.0000
20:5941136:GAGG:G	acceptor_gain	1.0000
20:5941140:C:CC	acceptor_gain	1.0000
20:5941341:TTAAA:T	acceptor_gain	1.0000
20:5941346:C:CC	acceptor_gain	1.0000
20:5941938:T:TA	donor_gain	1.0000
20:5941950:CCCAT:C	donor_gain	1.0000
20:5941973:G:C	donor_gain	1.0000
20:5942421:T:TA	donor_gain	1.0000
20:5942426:A:AC	donor_gain	1.0000
20:5942427:C:CC	donor_gain	1.0000
20:5942430:AAT:A	donor_gain	1.0000
20:5942443:T:TA	donor_gain	1.0000
20:5942455:AGGCC:A	donor_gain	1.0000
20:5942489:T:TA	donor_gain	1.0000
20:5942498:T:A	donor_gain	1.0000
20:5943554:CTTA:C	donor_loss	1.0000
20:5943556:TA:T	donor_loss	1.0000
20:5943557:A:AC	donor_gain	1.0000
20:5943557:ACCT:A	donor_gain	1.0000
20:5943557:ACCTC:A	donor_gain	1.0000
20:5943558:C:CC	donor_gain	1.0000
20:5943558:C:CT	donor_loss	1.0000
20:5943558:CCT:C	donor_gain	1.0000

AlphaMissense

3276 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:5938708:G:C	H441D	1.000
20:5944183:T:C	Y146C	1.000
20:5944184:A:G	Y146H	1.000
20:5944206:C:A	K138N	1.000
20:5944206:C:G	K138N	1.000
20:5944215:G:C	F135L	1.000
20:5944215:G:T	F135L	1.000
20:5944217:A:G	F135L	1.000
20:5944237:A:G	L128S	1.000
20:5944854:A:G	L106P	1.000
20:5944859:C:A	Q104H	1.000
20:5944859:C:G	Q104H	1.000
20:5944887:C:G	R95P	1.000
20:5938713:C:G	R439P	0.999
20:5941062:T:A	R431S	0.999
20:5941062:T:G	R431S	0.999
20:5941063:C:A	R431I	0.999
20:5941063:C:G	R431T	0.999
20:5944170:C:A	K150N	0.999
20:5944170:C:G	K150N	0.999
20:5944172:T:C	K150E	0.999
20:5944183:T:G	Y146S	0.999
20:5944184:A:C	Y146D	0.999
20:5944185:T:A	K145N	0.999
20:5944185:T:G	K145N	0.999
20:5944186:T:A	K145I	0.999
20:5944187:T:C	K145E	0.999
20:5944191:T:A	Q143H	0.999
20:5944191:T:G	Q143H	0.999
20:5944195:G:T	A142D	0.999

dbSNP variants (sampled 300 via entrez): RS1000293469 (20:5949977 G>A), RS1000402164 (20:5949304 T>C), RS1000696039 (20:5938532 G>A,C), RS1000922968 (20:5943797 T>C,G), RS1001425755 (20:5940761 G>A,T), RS1002243875 (20:5945106 G>T), RS1002343414 (20:5950566 G>T), RS1002418498 (20:5951055 A>G), RS1002504259 (20:5947732 C>A,G,T), RS1002856021 (20:5948198 G>A,C), RS1002967038 (20:5948037 T>C), RS1003562129 (20:5949248 C>T), RS1003648188 (20:5949127 T>G), RS1003734138 (20:5942548 A>G,T), RS1003855333 (20:5949930 G>A)

Disease associations

OMIM: gene MIM:620886 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000403_1	Menarche and menopause (age at onset)	1.000000e-21
GCST009158_7	Uterine fibroids	9.000000e-10
GCST012316_9	ghrelin levels	7.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004704	age at menopause
EFO:0600001	ghrelin measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Resveratrol	affects cotreatment, increases expression	2
Air Pollutants	increases oxidation, decreases expression, affects cotreatment, increases abundance	2
Valproic Acid	increases expression, decreases methylation	2
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
bisphenol A	decreases expression	1
deoxynivalenol	increases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
nickel sulfate	decreases expression	1
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment	1
ICG 001	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Sunitinib	increases expression	1
Acrolein	increases abundance, affects cotreatment, increases oxidation	1
Benzo(a)pyrene	increases mutagenesis	1
Coumestrol	affects cotreatment, increases expression	1
Dinitrochlorobenzene	affects binding	1
Estradiol	increases expression	1
Hydrogen Peroxide	affects expression	1
Nickel	increases expression	1
Ozone	increases oxidation, increases abundance, affects cotreatment	1
Plant Extracts	affects cotreatment, increases expression	1
Ribonucleotides	affects binding	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Cyclosporine	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.